Cambrian Biopharma's James Peyer: "70 will be the new 50"

episode

Times Tech not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Transrapid, Flugtaxis, Hyperloop – Warum es neuartige Verkehrstechnik so schwer hat 28 min · 22 Sep 2026 · Das Wissen | SWR

Las 10 de Erazno, el Chokolatazo, Parodias, Nacadas y mas 1h 25m · 22 Sep 2026 · Erazno y La Chokolata El Podcast

Cross-code immorality, Lachie Neale's strike, crowd behaviour - Andrew Voss | Across the Divide! (22.09.26) 17 min · 22 Sep 2026 · Whateley

S13 EP19: It's Exhausting Having an Opinion 37 min · 22 Sep 2026 · Parenting Hell with Rob Beckett and Josh Widdicombe

Fall in Love With the Life You Have 51 min · 22 Sep 2026 · The Candace Cameron Bure Podcast

NPR News: 09-21-2026 9PM EDT 5 min · 22 Sep 2026 · NPR News Now

Report any issue

Source

Recorded10 Dec 2021

Publisherfeeds.acast.com ↗

Handlerec:9725153

Show notes

The Sunday Times’ tech correspondent brings on James Peyer, co-founder of Cambrian Biopharma, to talk about the unique structure of his startup (6:30), the goal (8:45), alighting on longevity as a 15-year-old (12:45), why the field has matured (15:40), what he chooses to focus on (19:50), getting drugs to market (24:55), raising money (32:00), why he chose the name (38:30), why dying of old age not necessarily an evolutionary inevitability (41:00), and the vaccine model (45:00), Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in